Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs DraftKings Inc (DKNG) Price & Performance

BioNano Genomics IncTrade
DraftKings IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs DraftKings Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while DraftKings Inc trades at $25.75 (market cap $12.58B). The key difference: DraftKings Inc is far larger — about 920.9× BioNano Genomics Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGODKNG
Market Cap
$13.66M$12.58B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$48.23
52-Week Low
$1.06$20.72
Enterprise Value
$16.26M$13.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.

The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.

DraftKings Inc

DraftKings (DKNG) trades at $25.65, up 5.69% on the day, with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 results, missing earnings estimates but showing robust prediction market growth. Revenue reached $6.05B in 2025, with positive net income of $3.71M, marking a significant turnaround from prior losses. Cash flow from operations improved to $662.86M, though net cash flow turned negative in 2026 projections.

The outlook is cautiously optimistic, driven by prediction market expansion and cost management, but risks include intense competition and promotional pressures. With a consensus price target of $34.00 and 73% buy ratings, upside potential exists if execution continues. Investors should weigh growth prospects against valuation premiums and earnings volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG